| Patrick D Macken, MD | |
|
1425 Elderberry Ln, Eau Claire, WI 54701-9425 | |
| (715) 832-9801 | |
| Not Available |
| Full Name | Patrick D Macken |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Nephrology |
| Location | 1425 Elderberry Ln, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003872417 | NPI | - | NPPES |
| 31073900 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 20307 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Patrick D Macken, MD 1425 Elderberry Ln, Eau Claire, WI 54701-9425 Ph: (715) 832-9801 | Patrick D Macken, MD 1425 Elderberry Ln, Eau Claire, WI 54701-9425 Ph: (715) 832-9801 |
News Archive
Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.
A new analysis of two long-term studies has revealed a potential association between malignant melanoma risk and frequent consumption of grapefruit and oranges. The study found that compared with people who consumed these fruits less than twice a week, those who had them at least 1.6 times a day were at a 36% higher risk of developing melanoma.
According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab).
› Verified 5 days ago
Sandeep K Basu, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Myles David Keroack, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2116 Craig Rd, Eau Claire, WI 54701 Phone: 715-858-4500 | |
Rebecca M Kallunki, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Dr. Sameer Ahmad Batoo, MBBS Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Ali Zaied, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Allan J Sill, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 |